R&D | December 07, 2025
Bayer advances fight against rare kidney disease with new experimental drug
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
MRI is particularly valuable in pediatric care due to its non-invasive nature
Growing patent filings and tier-2 innovators reflect expanding national research base
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Here's a development that aims to keep your blood pressure in check. Literally!
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Subscribe To Our Newsletter & Stay Updated
